Compare ODC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | MNKD |
|---|---|---|
| Founded | 1941 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1994 | 2004 |
| Metric | ODC | MNKD |
|---|---|---|
| Price | $83.71 | $3.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.69 |
| AVG Volume (30 Days) | 64.6K | ★ 6.1M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 50.45 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | N/A | $11.89 |
| P/E Ratio | $49.75 | ★ N/A |
| Revenue Growth | 10.97 | ★ 22.23 |
| 52 Week Low | $45.61 | $2.23 |
| 52 Week High | $85.12 | $6.51 |
| Indicator | ODC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 70.19 | 53.91 |
| Support Level | $70.50 | $2.56 |
| Resistance Level | N/A | $3.94 |
| Average True Range (ATR) | 2.67 | 0.21 |
| MACD | 0.48 | -0.01 |
| Stochastic Oscillator | 88.15 | 47.52 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.